CYDY News and Press, CytoDyn Inc From 07/19/21

VANCOUVER, Washington, July 19, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today strong preliminary resul...

MicroStockHub/iStock via Getty Images CytoDyn (CYDY) says that its clinical development of leronlimab in combination with chemotherapy, carboplatin for the treatment of metastatic triple-negative breast cancer (mTNBC) has progressed from Phase 1b stage to a Phase 2 trial. Leronlimab...

CytoDyn anticipates preliminary efficacy data regarding potential responders in metastatic triple-negative breast cancer in approximately two weeks VANCOUVER, Washington, July 12, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biot...

VANCOUVER, Washington, July 06, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) , ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today its drug candidate, le...

CytoDyn (CYDY) has submitted a dose justification report to the FDA, which will be followed by an official submission to CytoDyn’s IND.The dose justification report is a key component for the BLA and includes receptor occupancy analysis, among other factors, to determine the optimal ma...

Management works to advance its BLA filing seeking FDA approval for leronlimab as a combination therapy for HIV patients while continuing its evaluation of other potential indications VANCOUVER, Washington, July 01, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) , ("CytoD...

Change Desperately Needed to Reverse Operational Failures, Underperformance, and Realize Significant Value Potential of Company’s Leronlimab Drug Sends Letter to Stockholders Urging Support of Nominees With Deeply Relevant Experience and Critical Independent Persp...

Competitors beating Merck for COVID-19 treatment. Proof of Molunupiravir efficacy is elusive. Merck's track record in this area is poor. For further details see: Merck Desperate To Get Back In Coronavirus Race, With A Pill

SAN DIEGO, CA / ACCESSWIRE / June 22, 2021 / The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in CytoDyn Inc. shares. Investors, who purchased shares of CytoDyn Inc. (OTCQB:CYDY) prior to March 2020 and continue to hold any of their (OTCQB:CYDY) sh...

CytoDyn ([[CYDY]]) announces preliminary results after unblinding the data from its COVID-19 long-haulers clinical trial.The purpose of the trial was to assess the safety and efficacy of leronlimab administered as weekly subcutaneous injection in subjects experiencing prolonged symptoms (>...